Tolerising antigen-specific immunotherapy for type 1 diabetes [ 1/1/2021 - 12/31/2023 ]

Research Grant

Brief description We have developed a new immunotherapy to treat the underlying causes of type 1 diabetes (T1D) while leaving the rest of the immune system intact. To use this in patients, we need better tests to know when immune therapy is working. We will develop new methods to design the therapy and tools to track the relevant immune cells in T1D that work in variable patient groups. The knowledge gained will speed the pace of development and increase the chance of success of immunotherapy in T1D.

Funding Amount $1,395,549

Funding Scheme Ideas Grants

Chief Investigator A/Pr Emma Hamilton-Williams

Notes Ideas Grants